Trial Profile
Efficacy, safety and metabolic impact of candesartan cilexetil/hydrochlorothiazide in patients with essential hypertension
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Nov 2015
Price :
$35
*
At a glance
- Drugs Candesartan cilexetil/hydrochlorothiazide (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- 19 Nov 2015 New trial record